Menu

Media

GSK's media centre

The latest GSK news and resources for journalists.

Press releasesAnnual Report 2025
Scientist in lab
Close video

Scroll to explore

To contact our global media relations team or sign up for alerts, please email  corporate.media@gsk.com.

For more contact details, please go to our media contacts page. 

Useful links

Latest press releases

For media and investors

06 October 2026

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia

15 September 2026

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

14 September 2026

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

13 September 2026

Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China

10 September 2026

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan

01 September 2026

GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data

24 August 2026

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

24 August 2026

Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

29 July 2026

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

28 July 2026

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK

28 July 2026

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

28 July 2026

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

27 July 2026

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

22 July 2026

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

21 July 2026

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

20 July 2026

European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds

17 July 2026

GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)

15 July 2026

GSK completes acquisition of Nuvalent, Inc.

13 July 2026

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

10 July 2026

GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

09 July 2026

Roy Jakobs to join GSK Board as Non-Executive Director

24 June 2026

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

17 June 2026

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

12 June 2026

GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

09 June 2026

GSK enters agreement to acquire Nuvalent, Inc.

28 May 2026

Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

26 May 2026

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA

18 May 2026

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk

11 May 2026

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

06 May 2026

GSK presents latest respiratory research to advance patient care at ATS 2026

29 April 2026

GSK delivers strong Q1 performance and start to 2026

28 April 2026

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

27 April 2026

GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

27 April 2026

TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation

20 April 2026

Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

15 April 2026

GSK completes acquisition of 35Pharma Inc.

12 April 2026

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers

08 April 2026

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

30 March 2026

Exdensur (depemokimab) approved in China for the treatment of severe asthma

30 March 2026

Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B

27 March 2026

Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B

23 March 2026

GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan

19 March 2026

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

13 March 2026

GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk

10 March 2026

GSK tops Antimicrobial Resistance (AMR) Benchmark Report

09 March 2026

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

03 March 2026

GSK completes acquisition of RAPT Therapeutics

26 February 2026

Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B

26 February 2026

Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis

25 February 2026

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

Search all press releases

In the spotlight

Luke Miels

2026 Third quarter

Quarterly results
28 October 2026

GSK’s third quarter 2026 results will be published via the London Stock Exchange at 07:00 GMT, 03:00 EDT on Wednesday, 28 October 2026.

The Company will host a live call for investors and analysts at 12:00 GMT, 08:00 EDT.

Science Image Multiple Myeloma RGB

2025 Annual Report and Responsible Business Performance Report published

Annual Report 2025
05 March 2025
Male scientist and female dressed smartly smiling in a studio

GSK at a glance

Quick facts and figures with a downloadable PDF

GSK at a glance

Behind the Science

Exploring how today's discoveries are shaping tomorrow's health

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

Behind the Science magazine

You might also like

Board of Directors and Executive Committee

GSK's Board oversees governance, strategy, risk and performance. Our CEO, supported by the Executive Committee, manages business operations.

Events calendar

Upcoming important dates in our financial calendar

Our social media

Explore our social media channels and access our social media community guidelines

Continue to Careers